Abstract
BackgroundImmunotherapy holds great promise for neuroblastoma. Implementation of anti-GD2 therapy improved patient survival rates substantially. However, many patients with neuroblastoma relapse and the 5-year survival rate for high-risk patients is...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
